It is generally assumed that there is symmetric distribution of the glucose transporter on the lumenal and ablumenal membranes of the brain capillary endothelial cell that makes up the blood-brain barrier (BBB) in vivo. However, the presence of brain endothelial tight junctions allows for asymmetric distribution of BBB plasma membrane proteins. Glucose transporter isoform 1 (GLUT-1), the prinicipal glucose transporter at the BBB, was assessed in rat brain in the present studies using immunogold electron microscopy. The distribution of the immunoreactive GLUT-1 protein on the endothelial lumenal membrane, the ablumenal membrane, and the cytoplasmic compartment was 12%, 48%, and 40%, respectively, and no significant immunolabeling of the neuropil was measurable. These studies suggest (i) that GLUT-1 is asymmetrically distributed on the BBB plasma membrane with an 4-fold greater abundance on the ablumenal membrane as compared to the lumenal membrane; (ii) that "40% of the endothelial glucose transporter protein is contained within the cytoplasmic space, which provides a mechanism for rapid up-regulation of the transporter by altered distribution of transporter between cytoplasmic and plasma membrane compartments; and (iii) that no significant labeling of neuropil is found with antisera directed against the GLUT-1 protein.
The major metabolic substrate of the brain is glucose, and the transport of glucose from blood to brain is tightly coupled with cerebral glucose utilization (1) . The transport of this important molecule into brain tissue is regulated at the brain capillary endothelial wall-i.e., the blood-brain barrier (BBB) (2, 3) . Glucose transport through this barrier is accomplished by the facilitated diffusion through two membranes in series, the lumenal and ablumenal endothelial membranes (4) , which are separated by -0.3 ,um of cytoplasm. Recent studies have established that glucose transporter isoform 1 (GLUT-1), which is a member of a sodiumindependent glucose transporter gene superfamily (5) , is quantitatively the most important, if not the only, glucose transporter isoform on the brain capillary endothelium (6) (7) (8) .
Pappenheimer and Setchell (4) emphasized that the transport of glucose through the BBB, although operationally treated as transport through a single membrane, actually represents transport through a double-membrane barrier. The single-membrane treatment has been used in a number of physiologic models of BBB glucose transport because (i) glucose equilibrates with the entire endothelial volume within milliseconds (9) , since this volume is only -0.1% of the total brain volume (10) , and (ii) it is generally found that the kinetic parameters ofglucose transport from blood-to-brain and from brain-to-blood are identical (4, 9, 11, 12) . However, the maximal transport capacity (Vma,) measured in these physiologic studies reflects the average concentration of active glucose transporters in the lumenal and ablumenal membranes (13) . Moreover, the brain capillary endothelial cell is endowed with epithelial-like tight junctions that cause polarization of the plasma membrane into lumenal and ablumenal compartments (14, 15) . This polarization could allow an asymmetric distribution of GLUT-1 between the two plasma membrane systems. Such an asymmetric distribution would have implications for the modulation of the BBB glucose transporter in pathologic and physiologic states (16 Perfusion Fixation. Rats were anesthetized with ketamine (100 mg/kg i.p.) and xylazine (2 mg/kg i.p.) and a PE-50 catheter was inserted into the aorta after thoracotomy. Physiological saline solution was perfused briefly to clear the vasculature and rats were then perfused with "200 ml of 2% (wt/vol) paraformaldehyde in 0.01 M sodium phosphate (pH 7.4) containing 0.01% glutaraldehyde, 0.9% NaCl, and CaCl2 (0.2 mg/ml). The brains were removed and small pieces of cortex were dissected and immersed in ice-cold fixative. The pieces were subsequently trimmed to 0.5-1.0 mm3 and immersed for 3 hr in the same fixative at 4'C.
Immersion Fixation. Animals were anesthetized and decapitated, and brains were immediately removed, followed by dissection of small sections of cortex, which were immersed in ice-cold 2% paraformaldehyde in 0.01 M sodium phosphate (pH 7.4) containing 0.9% NaCl, CaC12 (0.2 mg/ ml), 0.2 M sucrose, and 0.1% picric acid. These pieces were Abbreviations: GLUT-1, glucose transporter isoform 1; BBB, blood-brain barrier. *To whom reprint requests should be addressed at: Department of Medicine, Division of Endocrinology, UCLA School of Medicine, Los Angeles, CA 90024-1682.
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further trimmed to 0. Embedding and Sectioning. Brain was embedded in LRwhite (17) and then stained with immunogold. After fixation, all of the above tissues were rinsed in 0.1 M sodium phosphate (pH 7.4) and rapidly dehydrated through an ethanol series (10-min periods in 50%, 70%, 95%, and 100o ethanol) on ice followed by infiltration with LR-white [15-min periods in ethanol/LR-white 2:1, 1:1, and 1:2 (vol/wt)]. After at least three changes of fresh LR-white at room temperature, the tissues were blocked in gelatin capsules containing fresh LR-white, capped, and then polymerized overnight at 550C. Blocks of cortex were trimmed and semithin sections were cut and stained with toluidine blue. These sections were used to guide trimming for ultrathin sections. The cortical tissues were trimmed so that ultrathin sections included cortical layers II-IV. Two blocks of cortex per rat from eight rats were sectioned and sections were dried onto Formvar-coated nickel slot grids for staining.
Immunogold Procedures. Two rabbit polyclonal antisera directed against GLUT-1 were prepared in this laboratory and have been described (7) . The antiserum against the 13 amino acids at the C terminus of the protein is designated anti-CT and the antiserum prepared against purified human erythrocyte human glucose transporter protein is designated anti-hGT. These two primary antisera as well as preimmune serum were used at a dilution of 1:800 in 0.01 M sodium phosphate, pH 7.4/0.15 M NaCl/0.1% Tween 20/0.1% gelatin/1% bovine serum albumin (buffer A). Initially the sections were hydrated in buffer A and then incubated for 30 min at room temperature with 2.5% (wt/vol) ovalbumin and 2.5% (vol/vol) normal goat serum in buffer A. All antisera and preimmune or goat sera were filtered through Millipore GV filters. Grids were then incubated overnight at 4°C on drops of primary antiserum and the sections were then washed for six 10-min periods on large drops offiltered buffer A followed by incubation for 2 hr at room temperature in a 1:40 dilution of 10-nm-gold-particle-conjugated goat anti-rabbit immunoglobulin antiserum (Auroprobe EM-GAR10) diluted in buffer A, followed by washing for six 10-min periods on large drops of phosphate-buffered saline. The grids were then fixed for 5 min in 1% glutaraldehyde in 0.1 M Na2HPO4 (pH 7.4), rinsed with distilled water, stained with 2% (wt/vol) aqueous osmium tetraoxide for 10 min, rinsed with filtered water, stained with 2% (wt/vol) aqueous uranyl acetate for 30 min, rinsed with distilled water, and air-dried. Grids were examined in a JEOL electron microscope at 80 kV. Quantitation. Grids were scanned at x19,000 in the electron microscope and field counts were performed to quantify specificity of endothelial cell staining and to compare the endothelial immunolabeling with tissue background using both the preimmune and the respective antisera. For each study, immunogold particles were counted in -35 separate fields of neuropil, microvessel wall, and microvessel lumen. Microvessels were photographed in approximate crosssectional profile at x 14,000 for quantitation of subcellular distribution of immunostaining. The negatives were photographically enlarged to x38,000, and the immunogold particles of the lumenal membrane, the ablumenal membrane, and the cytoplasm profiles were counted. In these micrographs, the lumenal and ablumenal membranes were separated by a distance of 100-500 nm, which is large compared to the resolution (10-20 nm) of the immunogold procedure. The lumenal and ablumenal membranes were clearly distinguished by the differential density of the microvessel lumen, endothelial cytoplasm, and neuropil. The membrane distribution was quantified by measuring the membrane lengths and cytoplasmic areas by digitizing the lumenal and ablumenal perimeters of the endothelial cells in the microvessel profiles using a Sigma Scan image analyzer (Jandel Scientific, Corte Madera, CA length was examined from 105 microvessel profiles (-22 ,um of endothelial membrane length per profile). Statistical Analysis. Means from the individual rat brains treated with each fixative were compared using an analysis of variance to determine that there were no differences between the individual rats within the group. Data from three rats in each fixative group were then pooled to give a single mean and these means were compared using Student's t test and the Bonferroni correction for multiple comparisons. All data are presented as mean SD.
RESULTS
The structural preservation of the tissue was significantly better with paraformaldehyde/picric acid as opposed to the PLP immersion fixative. In the paraformaldehyde/picric acid-fixed cortex, the microvessels were relatively wellpreserved and remain intact within the surrounding neuropil (Fig. 1) . The ultrastructure of the microvessel endothelium in these preparations was also relatively well-preserved and many features of endothelial cells including junctional elements, plasma membranes, and basement membranes were identifiable ( Figs. 1 and 2 ). This structural preservation allowed for the quantification of the subcellular distribution of the immunogold particles (Fig. 2) .
The antigenicity of the transporter was sensitive to paraformaldehyde fixation and, accordingly, the duration of immersion fixation was restricted to 4 hr. The addition of glutaraldehyde concentrations above 0.01% significantly reduced antigenicity. The addition of picric acid improved the fixation of cellular elements but the concentration was restricted to 0.1%, as increasing the picric acid to 0.2% resulted in disruption of cell structure. Initially, rats were perfusion-fixed. However, a preliminary quantitative analysis of the GLUT-1 immunolabeling in these sections showed a 2-to 3-fold enrichment of the immunoreactive glucose transporter in the ablumenal membrane as compared to the lumenal membrane (Table 1) . These results suggested that perfusion fixation may result in a preferential loss of immunoreactive glucose transporter protein on the lumenal membrane. Therefore, immersion fixation protocols were subsequently examined in detail. In these studies, the specificity of antiserum labeling was assessed by field counts of gold particles at x 19,000 ( Table 2 ). The sections that were labeled with preimmune serum from the same animal were negative and had only a very low level of background labeling throughout the section. The immune antisera (anti-CT and anti-hGT) substantially labeled the microvessel endothelia as compared to the background labeling observed over the neuropil or vessel lumen (Table 2 ). Other components of the microvasculature were negative, as there was no detectable immunolabeling over pericytes, smooth muscle, basement membrane, or rat erythrocytes (Fig. 2) .
The data from the quantitation of the subcellular distribution of the immunogold labeling in either the paraformaldehyde/picric acid or PLP immersion-fixed specimens are presented in Table 3 , and these data also include the relative immunolabeling using either the anti-CT or anti-hGT antiserum. There were no significant differences in the gold particle distribution found in any instance due to use of either the anti-CT or anti-hGT antiserum. Significant differences were observed in comparing the anti-CT antiserum and the PLP fixative versus the same antiserum and the paraformaldehyde/picric acid fixative. The square area of endothelial .32 36 37 Brains were fixed with either PLP or PfPa and immunogold labeled with anti-CT or anti-hGT, as indicated. Data are mean + SD. PfPa, paraformaldehyde/picric acid; Au, single gold particle. *P < 0.001 difference between PLP (anti-CT) and PfPa (anti-CT).
cytoplasm was increased and the density ofgold particles per gm2 of either endothelial cell in the profiles or endothelial cytoplasm was reduced using the PLP fixative (Table 3) . These findings are attributed to cell swelling with the PLP fixative. However, neither the total amount of glucose transporters per profile nor the proportion of transporter found in the endothelial cell cytoplasm was significantly different when PLP and paraformaldehyde/picric acid fixatives were compared ( Table 3) .
The data in Table 3 demonstrate that there was no significant immunolabeling over the neuropil. In addition, the data show that the distribution of immunoreactive GLUT-1 over the microvessel endothelial, lumenal membrane, ablumenal membrane, and cytoplasm averaged 12%, 48%, and 40%, respectively. Immunoreactive transporters observed in tight junctional areas were classified as cytoplasmic transporters (Fig. 2) .
DISCUSSION
In the experiments reported herein, we used quantitative immunogold electron microscopy of GLUT-1 to demonstrate (i) an asymmetric localization of the immunoreactive transporter protein within the plasma membrane with an -4-fold greater abundance on the ablumenal membrane as compared to the lumenal membrane, (ii) a substantial pool of cytoplasmic immunoreactive glucose transporter amounting to '40% of the total endothelial immunoreactive protein, and (iii) no significant immunolabeling of the neuropil. Rat erythrocytes were also not measurably immunolabeled, and this finding is consistent with previous studies showing the concentration of glucose transporter in subhuman nonnucleated erythrocytes is <0.02% of the concentration of glucose transporter in human erythrocytes (18) (19) (20) .
The present finding of an asymmetric distribution of the immunoreactive glucose transporter between the lumenal and ablumenal membranes contrasts with a quantitative immunolocalization of GLUT-1 in PLP-perfusion-fixed dog brain, where a symmetric distribution of the transporter protein between the lumenal and ablumenal membranes was found (21) . Therefore, we considered three possible explanations for the asymmetric distribution observed in the present study. (i) We considered the asymmetric distribution was a fixation artifact. In our preliminary studies of the subcellular distribution of the transporter, we used perfusion fixation and hypothesized that the low density of lumenal labeling was a physical or chemical artifact of this procedure (Table 1) . Therefore, in subsequent more detailed studies, we employed immersion fixation and developed a paraformaldehyde/picric acid immersion fixation procedure that gave improved ultrastructure. However, the use of either the paraformaldehyde/picric acid or the PLP immersion fixation protocols gave essentially identical results with respect to the asymmetric distribution of the immunoreactive protein (Table 3). (ii) We considered that the low-density lumenal localization was a consequence of differential exposure of the C-terminal epitope in the lumenal membrane. Accordingly, the experiments in Table 3 employing the anti-CT antiserum were repeated with an antiserum prepared against the intact purified human erythrocyte glucose transporter (the antihGT antiserum). However, the use of these two antisera led to comparable results (Tables 2 and 3 ). (iii) We considered the possibility of a second glucose transporter preferentially localized to the lumenal membrane of the BBB. However, this explanation appears unlikely based on recent studies employing quantitative Western blot analysis and cytochalasin B radioreceptor assays (7) . The concentration of immunoreactive GLUT-1 in isolated brain microvessels, as determined by quantitative Western immunoblot analysis, was found not to be statistically different from the number of D-glucose-displaceable [3H]cytochalasin B binding sites in the brain microvessels (7) . These studies indicate GLUT-1 is the major, if not the only, glucose transporter at the BBB (8) . Therefore, the difference between this and a previous (21) study may represent fixation differences. Different fixation protocols may induce a shift in cytoplasmic glucose transporter to the lumenal membrane. The present finding of an asymmetric distribution of GLUT-1 at the BBB parallels an observation showing an asymmetric distribution of GLUT-2 on pancreatic 8-cell microvillar and sinusoidal membranes (22) .
The observation that the BBB glucose transporter is asymmetrically distributed between the lumenal and ablumenal membranes is not at odds with previous physiologic studies Proc. Natl. Acad. Sci. USA 88 (1991) 5783 showing essentially symmetric BBB permeabilities to glucose in the blood-to-brain and the brain-to-blood directions (9, 11, 23 (25) (26) (27) (28) .
Finally, these experiments demonstrate that GLUT-1 immunolabeling of brain is confined to the microvasculature with minimal significant immunolabeling of the neuropil. Thus, the present experiments support the hypothesis that GLUT-1 is specifically localized at the BBB in brain with minimal, if any, localization to neurons or glial cells (6, 7) . The isoform GLUT-1 was originally isolated by screening a cDNA library prepared with mRNA isolated initially from human hepatoma HepG2 cells (29) and subsequently from rat brain (30) with a polyclonal antiserum to the human erythrocyte glucose transporter. This isoform has alternatively been referred to as the erythroid-type or brain-type glucose transporter. Although initial Northern blot analyses (31) and immunocytochemical procedures (21, 32) demonstrated enrichment of GLUT-1 to the microvasculature, it was assumed that this isoform was also present in brain cells, and a recent study suggests GLUT-1 is a principal transporter for glial uptake of glucose (33) . However, quantitative Northern blot analyses, quantitative Western blot analyses, and in situ hybridization support the hypothesis that GLUT-1 is selectively expressed in microvascular endothelium with minimal, if any, expression in brain cells (6, 7) . In addition, the full-length GLUT-1 cDNA has been cloned from a brain capillary cDNA library (8) , and nucleotide sequencing shows this cDNA is essentially identical to the full-length GLUT-1 cDNA cloned from rat brain (30) .
In summary, the present studies demonstrate the asymmetric localization of GLUT-1 within the lumenal and ablumenal membranes of the BBB. This finding suggests a regulatory mechanism for transport of circulating glucose into the brain that involves redistribution of glucose transporter molecules in different subcellular compartments of the brain capillary endothelium. These studies also demonstrate a substantial cytoplasmic pool of endothelial glucose transporter and an analysis of the recruitment of intracellular glucose transporters to the plasma membrane may suggest an alternative approach to the investigation of the modulation of the BBB glucose transporter. Finally, these studies confirm the recent hypothesis that GLUT-1 is specifically localized to the BBB and that as yet unknown glucose transporters mediate sugar transport into glial cells and neurons. 
